Wedbush Reiterates Outperform on Fate Therapeutics, Maintains $7 Price Target
Benzinga Newsdesk 4 days ago
Analyst RatingsNewsReiterationPrice Target
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.
Wedbush analyst Martin Fan reiterates Fate Therapeutics (NASDAQ:FATE) with a Outperform and maintains $7 price target.